Humanigen has reported positive data from the first clinical use of lenzilumab, which is a humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, in 12 COVID-19 patients. Those treated with the drug fully recovered in 5 days. Yourway has been working throughout the pandemic to transport clinical trial materials to patients that need it, despite challenges involving border closure and supply chain disruptions.